Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRocView Video
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investorsView Video

Latest Share Chat

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,708.60
Bid: 1,708.40
Ask: 1,708.80
Change: 3.40 (0.20%)
Spread: 0.40 (0.023%)
Open: 1,701.60
High: 1,713.00
Low: 1,699.40
Prev. Close: 1,705.20
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: Citigroup And Goldman Downgrade Property Firms

Fri, 25th Jan 2019 09:47

LONDON (Alliance News) - The following London-listed shares received analyst recommendations Friday morning and late Thursday:----------FTSE 100----------GOLDMAN RAISES LAND SECURITIES TO 'NEUTRAL' ('SELL') - TARGET 769 (788) PENCE----------CITIGROUP CUTS LAND SECURITIES TO 'SELL' ('NEUTRAL') - TARGET 743 (974) PENCE----------GOLDMAN CUTS BRITISH LAND PRICE TARGET TO 589 (620) PENCE - 'NEUTRAL'----------CITIGROUP CUTS BRITISH LAND TO 'SELL' ('NEUTRAL') - TARGET 452 (647) PENCE----------GOLDMAN CUTS SEGRO PRICE TARGET TO 701 (716) PENCE - 'BUY'----------SOCGEN CUTS ITV TO 'HOLD' ('BUY') - TARGET 138 (190) PENCE----------SHORE CAPITAL RAISES ASTRAZENECA TO 'BUY' ('HOLD')----------HSBC SEES GLAXOSMITHKLINE AS ONE OF THE BEST GLOBAL STOCK IDEAS----------RBC CUTS BHP GROUP PRICE TARGET TO 1500 (1525) PENCE - 'SECTOR PERFORM'----------HSBC RAISES ANGLO AMERICAN PRICE TARGET TO 2120 (2100) PENCE - 'BUY'----------UBS RAISES FRESNILLO TO 'BUY' ('NEUTRAL') - TARGET 1100 (900) PENCE----------JPMORGAN CUTS KINGFISHER PRICE TARGET TO 200 (220) PENCE - 'UNDERWEIGHT'----------GOLDMAN RAISES AB FOODS PRICE TARGET TO 2600 (2500) PENCE - 'NEUTRAL'----------GOLDMAN RAISES SEVERN TRENT PRICE TARGET TO 1847 (1763) PENCE - 'SELL'----------BERNSTEIN CUTS VODAFONE PRICE TARGET TO 225 (235) PENCE - 'OUTPERFORM'----------JPMORGAN CUTS VODAFONE PRICE TARGET TO 230 (240) PENCE - 'OVERWEIGHT'----------DEUTSCHE BANK CUTS ST JAMES'S PLACE PRICE TARGET TO 1070 (1090) PENCE - 'HOLD'----------CREDIT SUISSE CUTS RBS PRICE TARGET TO 280 (295) PENCE - 'NEUTRAL'----------CREDIT SUISSE CUTS LLOYDS PRICE TARGET TO 84 (90) PENCE - 'OUTPERFORM'----------CREDIT SUISSE CUTS BARCLAYS PRICE TARGET TO 190 (210) PENCE - 'NEUTRAL'----------EXANE BNP RAISES HALMA TO 'OUTPERFORM' ('NEUTRAL') - TARGET 1550 (1350) PENCE----------EXANE BNP CUTS SPIRAX-SARCO TO 'UNDERPERFORM' (N) - TARGET 5700 (6300) PENCE----------FTSE 250----------GOLDMAN CUTS INTU PROPERTIES TO 'SELL' ('NEUTRAL') - TARGET 92 (117) PENCE----------CITIGROUP CUTS INTU PROPERTIES TO 'SELL' ('NEUTRAL') - TARGET 69 (190) PENCE----------CITIGROUP CUTS HAMMERSON TO 'SELL' ('NEUTRAL') - TARGET 278 (465) PENCE----------GOLDMAN CUTS HAMMERSON PRICE TARGET TO 367 (441) PENCE - 'NEUTRAL'----------CITIGROUP CUTS GREAT PORTLAND TO 'SELL' ('NEUTRAL') - TARGET 592 (691) PENCE----------GOLDMAN CUTS GREAT PORTLAND PRICE TARGET TO 633 (662) PENCE - 'NEUTRAL'----------GOLDMAN CUTS DERWENT LONDON PRICE TARGET TO 2960 (2976) PENCE - 'NEUTRAL'----------CITIGROUP CUTS DERWENT LONDON TO 'SELL' ('NEUTRAL') - TARGET 2513 (3186) PENCE----------GOLDMAN CUTS SHAFTESBURY PRICE TARGET TO 748 (806) PENCE - 'SELL'----------CITIGROUP CUTS SHAFTESBURY TO 'NEUTRAL' ('BUY') - TARGET 872 (1229) PENCE----------GOLDMAN CUTS BIG YELLOW GROUP PRICE TARGET TO 972 (993) PENCE - 'NEUTRAL'----------UBS CUTS CAPITAL & COUNTIES PRICE TARGET TO 310 (320) PENCE - 'BUY'----------JPMORGAN CUTS TRAVIS PERKINS PRICE TARGET TO 1330 (1400) PENCE - 'NEUTRAL'----------HSBC INITIATES CRANSWICK WITH 'HOLD' - TARGET 2810 PENCE----------HSBC INITIATES DAIRY CREST GROUP WITH 'BUY' - TARGET 570 PENCE----------HSBC INITIATES GREENCORE WITH 'BUY' - TARGET 270 PENCE----------HSBC INITIATES HILTON FOOD WITH 'HOLD' - TARGET 920 PENCE----------EXANE BNP RAISES PHOENIX GROUP TARGET TO 800 PENCE - 'OUTPERFORM'----------UBS CUTS SOPHOS PRICE TARGET TO 400 (440) PENCE - 'BUY'----------LIBERUM RESUMES RESTAURANT GROUP WITH 'HOLD' - TARGET 180 PENCE----------EXANE BNP CUTS SPECTRIS TO 'NEUTRAL' ('OUTPERFORM') - TARGET 2350 (2550) PENCE----------OTHER MAIN MARKET AND AIM----------CREDIT SUISSE CUTS DAILY MAIL PRICE TARGET TO 685 (770) PENCE - 'NEUTRAL'---------BARCLAYS CUTS DAILY MAIL PRICE TARGET TO 570 (605) PENCE - 'UNDERWEIGHT'----------GOLDMAN CUTS SECURE INCOME REIT PRICE TARGET TO 417 (446) PENCE - 'BUY'----------RBC CUTS FEVERTREE DRINKS PRICE TARGET TO 3400 (3600) PENCE - 'OUTPERFORM'----------DEUTSCHE BANK RAISES FEVERTREE DRINKS TARGET TO 2800 (2700) PENCE - 'HOLD'----------BERENBERG RAISES CONNECT GROUP PRICE TARGET TO 40 (35) PENCE - 'HOLD'----------LIBERUM RESUMES BURFORD CAPITAL WITH 'BUY' - TARGET 2300 PENCE----------

More News
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.